ePharmacy Market Research Report Information By Drug Type (Prescription Drugs, and Over the Counter (OTC) Drugs), By Operating Platform (App and Website), By Business Model (Pharmacy and Direct), And By Region (Europe, Asia-Pacific, North America, And Rest Of The World) – Market Forecast Till 2032

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY 16

1.1 OVERVIEW 16

1.1.1 MARKET SYNOPSIS 16

2 MARKET INTRODUCTION 17

2.1 SCOPE OF THE STUDY 17

2.2 RESEARCH OBJECTIVE 17

2.3 LIST OF ASSUMPTIONS 17

3 RESEARCH METHODOLOGY 19

3.1 OVERVIEW 19

3.2 DATA MINING 19

3.3 SECONDARY RESEARCH 20

3.4 PRIMARY RESEARCH 21

3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 21

3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 22

3.5 FORECASTING TECHNIQUES 22

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 23

3.6.1 BOTTOM-UP APPROACH 24

3.6.2 TOP-DOWN APPROACH 25

3.7 DATA TRIANGULATION 25

3.8 VALIDATION 25

4 MARKET DYNAMICS 26

4.1 OVERVIEW 26

4.2 DRIVERS 27

4.2.1 RISING ADOPTION RATE OF INTERNET AND HEALTHCARE APPS 27

4.2.2 RISING OCCURRENCE OF CHRONIC AND INFECTIOUS DISEASES 27

4.2.3 INCREASING GERIARTIC POPULATION 27

4.3 RESTRAINTS 28

4.3.1 COUNTERFEIT MEDICINES 28

4.4 OPPORTUNITIES 29

4.4.1 NEED FOR EPHARMACY SERVICES IN EMERGING ECONOMIES 29

5 MARKET FACTOR ANALYSIS 30

5.1 PORTER’S FIVE FORCES MODEL 30

5.1.1 THREAT OF NEW ENTRANTS 30

5.1.2 BARGAINING POWER OF SUPPLIERS 31

5.1.3 THREAT OF SUBSTITUTES 31

5.1.4 BARGAINING POWER OF BUYERS 31

5.1.5 INTENSITY OF RIVALRY 31

5.2 VALUE CHAIN ANALYSIS 32

5.2.1 INPUTS 32

5.2.2 SOFTWARE DEVELOPMENT PROCESSES 33

5.2.3 OUTPUT 33

5.2.4 MARKETING AND DISTRIBUTION 33

5.2.5 POST-SALES MONITORING 33

5.3 IMPACT OF COVID 19 ON EPHARMACY MARKET 34

5.3.3 IMPACT ON COST OF PRODUCT/SOFTWARE 35

5.3.1 IMPACT ON ADOPTION OF SOFTWARE 34

5.3.2 IMPACT ON ADOPTION OF CLOUD-BASED TECHNOLOGIES 35

6 GLOBAL EPHARMACY MARKET, BY DRUG TYPE 37

6.1 OVERVIEW 37

6.2 PRESCRIPTION DRUGS 39

6.3 OVER THE COUNTER (OTC) DRUGS 40

7 GLOBAL EPHARMACY MARKET, BY OPERATING PLATFORM 48

7.1 OVERVIEW 48

7.2 APP 50

7.3 WEBSITE 50

8 GLOBAL EPHARMACY MARKET, BY BUSINESS MODEL 51

8.1 OVERVIEW 52

8.2 MARKETPLACE 54

8.3 PHARMACY 55

8.4 DIRECT 56

9 GLOBAL EPHARMACY MARKET, BY REGION 58

9.1 OVERVIEW 58

9.2 AMERICAS 60

9.2.1 NORTH AMERICA 62

9.2.1.1 US 65

9.2.1.2 CANADA 67

9.2.2 LATIN AMERICA 69

9.3 EUROPE 71

9.3.1 WESTERN EUROPE 74

9.3.1.1 GERMANY 76

9.3.1.2 FRANCE 78

9.3.1.3 UK 79

9.3.1.4 ITALY 81

9.3.1.5 SPAIN 82

9.3.1.6 REST OF WESTERN EUROPE 84

9.3.2 EASTERN EUROPE 86

9.4 ASIA-PACIFIC 88

9.4.1 CHINA 91

9.4.2 JAPAN 92

9.4.3 INDIA 94

9.4.4 AUSTRALIA 95

9.4.5 SOUTH KOREA 97

9.4.6 REST OF ASIA-PACIFIC 98

9.5 MIDDLE EAST AND AFRICA 100

9.5.1 MIDDLE EAST 102

9.5.2 AFRICA 104

10 COMPETITIVE LANDSCAPE 106

10.1 OVERVIEW 106

10.2 COMPETITIVE BENCHMARKING 107

10.3 COMPETITOR DASHBOARD 108

10.4 MAJOR GROWTH STRATEGY IN THE GLOBAL EPHARMACY MARKET 109

10.5 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL EPHARMACY MARKET 110

10.6 KEY DEVELOPMENT ANALYSIS 110

10.7 KEY DEVELOPMENTS & GROWTH STRATEGIES 111

10.7.1 ACQUISITION ACTIVITIES 111

10.7.2 NEW PRODUCTS/SERVICE LAUNCHES 112

10.7.3 COLLABORATIONS 113

10.7.4 PARTNERSHIPS 113

10.7.5 APPROVALS 113

11 COMPANY PROFILES 114

11.1 WALGREENS BOOTS ALLIANCE, INC.. 114

11.1.1 COMPANY OVERVIEW 114

11.1.2 FINANCIAL OVERVIEW 115

11.1.3 PRODUCTS/SERVICES OFFERED 116

11.1.4 KEY DEVELOPMENTS 117

11.1.5 SWOT ANALYSIS 118

11.1.6 KEY STRATEGIES 118

11.2 WAL-MART, INC. 119

11.2.1 COMPANY OVERVIEW 119

11.2.2 FINANCIAL OVERVIEW 119

11.2.3 PRODUCTS/SERVICES OFFERED 120

11.2.4 KEY DEVELOPMENTS 120

11.2.5 SWOT ANALYSIS 121

11.2.6 KEY STRATEGIES 121

11.3 CVS HEALTH... 122

11.3.1 COMPANY OVERVIEW 122

11.3.2 FINANCIAL OVERVIEW 123

11.3.3 PRODUCTS/SERVICES OFFERED 123

11.3.4 KEY DEVELOPMENTS 124

11.3.5 SWOT ANALYSIS 125

11.3.6 KEY STRATEGIES 125

11.4 DR. FOX PHARMACY 126

11.4.1 COMPANY OVERVIEW 126

11.4.2 FINANCIAL OVERVIEW 126

11.4.3 PRODUCTS/SERVICES OFFERED 127

11.4.4 KEY DEVELOPMENTS 127

11.4.5 SWOT ANALYSIS 128

11.4.6 KEY STRATEGIES 128

11.5 DOCMORRIS N.V. 129

11.5.1 COMPANY OVERVIEW 129

11.5.2 FINANCIAL OVERVIEW 129

11.5.3 PRODUCTS/SERVICES OFFERED 130

11.5.4 KEY DEVELOPMENTS 131

11.5.5 SWOT ANALYSIS 131

11.5.6 KEY STRATEGIES 131

11.6 ROWLANDS PHARMACY.. 132

11.6.1 COMPANY OVERVIEW 132

11.6.2 FINANCIAL OVERVIEW 132

11.6.3 PRODUCTS/SERVICES OFFERED 133

11.6.4 KEY DEVELOPMENTS 133

11.6.5 SWOT ANALYSIS 133

11.6.6 KEY STRATEGIES 134

11.7 OPTUMRX. 135

11.7.1 COMPANY OVERVIEW 135

11.7.2 FINANCIAL OVERVIEW 135

11.7.3 PRODUCTS/SERVICES OFFERED 136

11.7.4 KEY DEVELOPMENTS 136

11.7.5 SWOT ANALYSIS 137

11.7.6 KEY STRATEGIES 137

11.8 THE ONLINE DRUGSTORE. 138

11.8.1 COMPANY OVERVIEW 138

11.8.2 FINANCIAL OVERVIEW 138

11.8.3 PRODUCTS/SERVICES OFFERED 139

11.8.4 KEY DEVELOPMENTS 139

11.8.5 SWOT ANALYSIS 140

11.8.6 KEY STRATEGIES 140

11.9 WELL PHARMACY 141

11.9.1 COMPANY OVERVIEW 141

11.9.2 FINANCIAL OVERVIEW 141

11.9.3 KEY DEVELOPMENTS 142

11.9.4 SWOT ANALYSIS 143

11.9.5 KEY STRATEGIES 143

11.10 LLOYDSPHARMACY 144

11.10.1 COMPANY OVERVIEW 144

11.10.2 FINANCIAL OVERVIEW 145

11.10.3 PRODUCTS/SERVICES OFFERED 146

11.10.4 KEY DEVELOPMENTS 146

11.10.5 SWOT ANALYSIS 146

11.10.6 KEY STRATEGIES 147

12 APPENDIX 148

12.1 REFERENCES 148

12.2 RELATED REPORTS 148

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS 17

TABLE 2 GLOBAL EPHARMACY MARKET, BY DRUG TYPE, 2018–2030 (USD MILLION) 39

TABLE 3 GLOBAL EPHARMACY MARKET, FOR PRESCRIPTION DRUGS, BY REGION, 2018–2030 (USD MILLION) 40

TABLE 4 GLOBAL EPHARMACY MARKET, FOR OVER THE COUNTER (OTC) DRUGS, BY REGION, 2018–2030 (USD MILLION) 40

TABLE 5 GLOBAL EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2030 (USD MILLION) 49

TABLE 6 GLOBAL EPHARMACY MARKET, FOR APP, BY REGION, 2018–2030 (USD MILLION) 50

TABLE 7 GLOBAL EPHARMACY MARKET, FOR WEBSITE, BY REGION, 2018–2030 (USD MILLION) 51

TABLE 8 GLOBAL EPHARMACY MARKET, BY BUSINESS MODEL, 2018–2030 (USD MILLION) 49

TABLE 9 GLOBAL EPHARMACY MARKET, FOR MARKETPLACE, BY REGION, 2018–2030 (USD MILLION) 50

TABLE 10 GLOBAL EPHARMACY MARKET, FOR PHARMACY, BY REGION, 2018–2030 (USD MILLION) 51

TABLE 11 GLOBAL EPHARMACY MARKET, FOR DIRECT, BY REGION, 2018–2030 (USD MILLION) 51

TABLE 12 GLOBAL EPHARMACY MARKET, BY REGION, 2018–2030 (USD MILLION) 59

TABLE 13 AMERICAS: EPHARMACY MARKET, BY REGION, 2018–2030 (USD MILLION) 60

TABLE 14 AMERICAS: EPHARMACY MARKET, BY DRUG TYPE, 2018–2030 (USD MILLION) 61

TABLE 15 AMERICAS: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2030 (USD MILLION) 61

TABLE 16 AMERICAS: EPHARMACY MARKET, BY BUSINESS MODEL, 2018–2030 (USD MILLION) 49

TABLE 17 NORTH AMERICA: EPHARMACY MARKET, BY COUNTRY, 2018–2030 (USD MILLION) 63

TABLE 18 NORTH AMERICA: EPHARMACY MARKET, BY DRUG TYPE, 2018–2030 (USD MILLION) 63

TABLE 19 NORTH AMERICA: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2030 (USD MILLION) 64

TABLE 20 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2018–2030 (USD MILLION) 49

TABLE 21 US: EPHARMACY MARKET, BY DRUG TYPE, 2018–2030 (USD MILLION) 65

TABLE 22 US: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2030 (USD MILLION) 66

TABLE 23 US: EPHARMACY MARKET, BY BUSINESS MODEL, 2018–2030 (USD MILLION) 49

TABLE 24 CANADA: EPHARMACY MARKET, BY DRUG TYPE, 2018–2030 (USD MILLION) 67

TABLE 25 CANADA: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2030 (USD MILLION) 68

TABLE 26 CANADA: EPHARMACY MARKET, BY BUSINESS MODEL, 2018–2030 (USD MILLION) 49

TABLE 27 LATIN AMERICA: EPHARMACY MARKET, BY DRUG TYPE, 2018–2030 (USD MILLION) 69

TABLE 28 LATIN AMERICA: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2030 (USD MILLION) 69

TABLE 29 LATIN AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2018–2030 (USD MILLION) 49

TABLE 30 EUROPE: EPHARMACY MARKET, BY REGION, 2018–2030 (USD MILLION) 71

TABLE 31 EUROPE: EPHARMACY MARKET, BY DRUG TYPE, 2018–2030 (USD MILLION) 72

TABLE 32 EUROPE: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2030 (USD MILLION) 73

TABLE 33 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2018–2030 (USD MILLION) 49

TABLE 34 WESTERN EUROPE: EPHARMACY MARKET, BY COUNTRY, 2018–2030 (USD MILLION) 74

TABLE 35 WESTERN EUROPE: EPHARMACY MARKET, BY DRUG TYPE, 2018–2030 (USD MILLION) 75

TABLE 36 WESTERN EUROPE: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2030 (USD MILLION) 75

TABLE 37 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2018–2030 (USD MILLION) 49

TABLE 38 GERMANY: EPHARMACY MARKET, BY DRUG TYPE, 2018–2030 (USD MILLION) 76

TABLE 39 GERMANY: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2030 (USD MILLION) 77

TABLE 40 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2018–2030 (USD MILLION) 49

TABLE 41 FRANCE: EPHARMACY MARKET, BY DRUG TYPE, 2018–2030 (USD MILLION) 78

TABLE 42 FRANCE: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2030 (USD MILLION) 78

TABLE 43 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2018–2030 (USD MILLION) 49

TABLE 44 UK: EPHARMACY MARKET, BY DRUG TYPE, 2018–2030 (USD MILLION) 79

TABLE 45 UK: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2030 (USD MILLION) 80

TABLE 46 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2018–2030 (USD MILLION) 49

TABLE 47 ITALY: EPHARMACY MARKET, BY DRUG TYPE, 2018–2030 (USD MILLION) 81

TABLE 48 ITALY: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2030 (USD MILLION) 81

TABLE49 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2018–2030 (USD MILLION) 49

TABLE 50 SPAIN: EPHARMACY MARKET, BY DRUG TYPE, 2018–2030 (USD MILLION) 82

TABLE 51 SPAIN: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2030 (USD MILLION) 83

TABLE 52 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2018–2030 (USD MILLION) 49

TABLE 53 REST OF WESTERN EUROPE: EPHARMACY MARKET, BY DRUG TYPE, 2018–2030 (USD MILLION) 84

TABLE 54 REST OF WESTERN EUROPE: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2030 (USD MILLION) 85

TABLE 55 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2018–2030 (USD MILLION) 49

TABLE 56 EASTERN EUROPE: EPHARMACY MARKET, BY DRUG TYPE, 2018–2030 (USD MILLION) 86

TABLE 57 EASTERN EUROPE: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2030 (USD MILLION) 86

TABLE 58 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2018–2030 (USD MILLION) 49

TABLE 59 ASIA-PACIFIC: EPHARMACY MARKET, BY COUNTRY, 2018–2030 (USD MILLION) 88

TABLE 60 ASIA-PACIFIC: EPHARMACY MARKET, BY DRUG TYPE, 2018–2030 (USD MILLION) 89

TABLE 61 ASIA-PACIFIC: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2030 (USD MILLION) 90

TABLE 62 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2018–2030 (USD MILLION) 49

TABLE 63 CHINA: EPHARMACY MARKET, BY DRUG TYPE, 2018–2030 (USD MILLION) 91

TABLE 64 CHINA: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2030 (USD MILLION) 91

TABLE 65 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2018–2030 (USD MILLION) 49

TABLE 66 JAPAN: EPHARMACY MARKET, BY DRUG TYPE, 2018–2030 (USD MILLION) 92

TABLE 67 JAPAN: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2030 (USD MILLION) 93

TABLE 68 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2018–2030 (USD MILLION) 49

TABLE 69 INDIA: EPHARMACY MARKET, BY DRUG TYPE, 2018–2030 (USD MILLION) 94

TABLE 70 INDIA: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2030 (USD MILLION) 94

TABLE 71 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2018–2030 (USD MILLION) 49

TABLE 72 AUSTRALIA: EPHARMACY MARKET, BY DRUG TYPE, 2018–2030 (USD MILLION) 95

TABLE 73 AUSTRALIA: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2030 (USD MILLION) 96

TABLE 74 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2018–2030 (USD MILLION) 49

TABLE 75 SOUTH KOREA: EPHARMACY MARKET, BY DRUG TYPE, 2018–2030 (USD MILLION) 97

TABLE 76 SOUTH KOREA: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2030 (USD MILLION) 97

TABLE 77 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2018–2030 (USD MILLION) 49

TABLE 78 REST OF ASIA-PACIFIC: EPHARMACY MARKET, BY DRUG TYPE, 2018–2030 (USD MILLION) 98

TABLE 79 REST OF ASIA-PACIFIC: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2030 (USD MILLION) 99

TABLE 80 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2018–2030 (USD MILLION) 49

TABLE 81 MIDDLE EAST AND AFRICA: EPHARMACY MARKET, BY REGION, 2018–2030 (USD MILLION) 100

TABLE 82 MIDDLE EAST AND AFRICA: EPHARMACY MARKET, BY DRUG TYPE, 2018–2030 (USD MILLION) 101

TABLE 83 MIDDLE EAST AND AFRICA: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2030 (USD MILLION) 101

TABLE 84 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2018–2030 (USD MILLION) 49

TABLE 85 MIDDLE EAST: EPHARMACY MARKET, BY DRUG TYPE, 2018–2030 (USD MILLION) 102

TABLE 86 MIDDLE EAST: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2030 (USD MILLION) 103

TABLE 87 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2018–2030 (USD MILLION) 49

TABLE 88 AFRICA: EPHARMACY MARKET, BY DRUG TYPE, 2018–2030 (USD MILLION) 104

TABLE 89 AFRICA: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2030 (USD MILLION) 104

TABLE 90 NORTH AMERICA: EPHARMACY MARKET, BY BUSINESS MODEL, 2018–2030 (USD MILLION) 49

TABLE 91 MAJOR MANUFACTURERS IN THE GLOBAL EPHARMACY MARKET 106

TABLE 92 BENCHMARKING OF MAJOR COMPETITORS 107

TABLE 93 COMPETITOR DASHBOARD: GLOBAL EPHARMACY MARKET 108

TABLE 94 MOST ACTIVE PLAYER IN THE GLOBAL EPHARMACY MARKET 110

TABLE 95 ACQUISITION ACTIVITIES 111

TABLE 96 NEW PRODUCTS/SERVICE LAUNCHES 112

TABLE 97 COLLABORATIONS 113

TABLE 98 PARTNERSHIPS 113

TABLE 99 APPROVALS 113

TABLE 100 WALGREENS BOOTS ALLIANCE, INC.: PRODUCTS/SERVICES OFFERED 116

TABLE 101 WALGREENS BOOTS ALLIANCE, INC.: KEY DEVELOPMENTS 117

TABLE 102 WAL-MART, INC.: PRODUCTS/SERVICES OFFERED 120

TABLE 103 WAL-MART, INC.: KEY DEVELOPMENTS 120

TABLE 104 CVS HEALTH: PRODUCTS/SERVICES OFFERED 123

TABLE 105 CVS HEALTH: KEY DEVELOPMENTS 124

TABLE 106 DR. FOX PHARMACY: PRODUCTS/SERVICES OFFERED 127

TABLE 107 DR. FOX PHARMACY: KEY DEVELOPMENTS 127

TABLE 108 DOCMORRIS N.V.: PRODUCTS/SERVICES OFFERED 130

TABLE 109 DOCMORRIS N.V.: KEY DEVELOPMENTS 131

TABLE 110 ROWLANDS PHARMACY: PRODUCTS/SERVICES OFFERED 133

TABLE 111 OPTUMRX: PRODUCTS/SERVICES OFFERED 136

TABLE 112 OPTUMRX: KEY DEVELOPMENTS 136

TABLE 113 THE ONLINE DRUGSTORE: PRODUCTS/SERVICES OFFERED 139

TABLE 114 THE ONLINE DRUGSTORE LIFESCIENCES HOLDINGS CORPORATION: KEY DEVELOPMENTS 139

TABLE 115 WELL PHARMACY: PRODUCTS/SERVICES OFFERED 142

TABLE 116 WELL PHARMACY: KEY DEVELOPMENTS 142

TABLE 117 LLOYDSPHARMACY: PRODUCTS/SERVICES OFFERED 146

TABLE 118 LLOYDSPHARMACY: KEY DEVELOPMENTS 146

LIST OF FIGURES

FIGURE 1 GLOBAL EPHARMACY MARKET STRUCTURE 18

FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES 24

FIGURE 3 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL EPHARMACY MARKET 26

FIGURE 4 PORTER’S FIVE FORCES ANALYSIS: GLOBAL EPHARMACY MARKET 30

FIGURE 5 VALUE CHAIN ANALYSIS OF THE GLOBAL EPHARMACY MARKET 32

FIGURE 6 GLOBAL EPHARMACY MARKET SHARE, BY DRUG TYPE, 2019 (%) 37

FIGURE 7 GLOBAL EPHARMACY MARKET, BY DRUG TYPE, 2019 AND 2030 (USD MILLION) 38

FIGURE 8 GLOBAL EPHARMACY MARKET SHARE, BY OPERATING PLATFORM, 2019 (%) 48

FIGURE 9 GLOBAL EPHARMACY MARKET, BY OPERATING PLATFORM, 2019 AND 2030 (USD MILLION) 49

FIGURE 10 GLOBAL EPHARMACY MARKET SHARE, BY BUSINESS MODEL, 2019 (%) 48

FIGURE 11 GLOBAL EPHARMACY MARKET, BY BUSINESS MODEL, 2019 AND 2030 (USD MILLION) 49

FIGURE 12 GLOBAL EPHARMACY MARKET SHARE, BY REGION, 2019 (%) 58

FIGURE 13 GLOBAL EPHARMACY MARKET, BY REGION, 2019 AND 2030 (USD MILLION) 58

FIGURE 14 AMERICAS: EPHARMACY MARKET, BY REGION, 2019 AND 2030 (USD MILLION) 60

FIGURE 15 NORTH AMERICA: EPHARMACY MARKET, BY COUNTRY, 2019 AND 2030 (USD MILLION) 62

FIGURE 16 EUROPE: EPHARMACY MARKET, BY REGION, 2019 AND 2030 (USD MILLION) 71

FIGURE 17 WESTERN EUROPE: EPHARMACY MARKET, BY COUNTRY, 2019 AND 2030 (USD MILLION) 74

FIGURE 18 ASIA-PACIFIC: EPHARMACY MARKET, BY COUNTRY, 2019 AND 2030 (USD MILLION) 88

FIGURE 19 MIDDLE EAST AND AFRICA: EPHARMACY MARKET, BY REGION, 2019 AND 2030 (USD MILLION) 100

FIGURE 20 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN GLOBAL EPHARMACY MARKET 109

FIGURE 21 GLOBAL EPHARMACY MARKET, COMPETITIVE LANDSCAPE 110

FIGURE 22 WALGREENS BOOTS ALLIANCE, INC.: FINANCIAL OVERVIEW SNAPSHOT 115

FIGURE 23 WALGREENS BOOTS ALLIANCE, INC.: SWOT ANALYSIS 118

FIGURE 24 WAL-MART, INC.: FINANCIAL OVERVIEW SNAPSHOT 119

FIGURE 25 WAL-MART, INC.: SWOT ANALYSIS 121

FIGURE 26 CVS HEALTH: FINANCIAL OVERVIEW SNAPSHOT 123

FIGURE 27 CVS HEALTH: SWOT ANALYSIS 125

FIGURE 28 DR. FOX PHARMACY: FINANCIAL OVERVIEW SNAPSHOT 126

FIGURE 29 DR. FOX PHARMACY: SWOT ANALYSIS 128

FIGURE 30 DOCMORRIS N.V.: FINANCIAL OVERVIEW SNAPSHOT 129

FIGURE 31 DOCMORRIS N.V.: SWOT ANALYSIS 131

FIGURE 32 ROWLANDS PHARMACY: FINANCIAL OVERVIEW SNAPSHOT 132

FIGURE 33 ROWLANDS PHARMACY: SWOT ANALYSIS 133

FIGURE 34 OPTUMRX: FINANCIAL OVERVIEW SNAPSHOT 135

FIGURE 35 OPTUMRX: SWOT ANALYSIS 137

FIGURE 36 THE ONLINE DRUGSTORE: FINANCIAL OVERVIEW SNAPSHOT 138

FIGURE 37 THE ONLINE DRUGSTORE LIFESCIENCES HOLDINGS CORPORATION: SWOT ANALYSIS 140

FIGURE 38 WELL PHARMACY: FINANCIAL OVERVIEW SNAPSHOT 141

FIGURE 39 WELL PHARMACY: SWOT ANALYSIS 143

FIGURE 40 LLOYDSPHARMACY: FINANCIAL OVERVIEW SNAPSHOT 145

FIGURE 41 LLOYDSPHARMACY: SWOT ANALYSIS 146